Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy

Abstract Objectives To assess immunogenicity and safety of the 23-valent polysaccharide pneumococcal vaccine (PPV23) in juvenile idiopathic arthritis (JIA) patients under conventional DMARDs with or without anti-TNF therapy. The influences of demographic data, disease activity and treatment on immun...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2015-01, Vol.33 (5), p.604-609
Hauptverfasser:	Aikawa, Nadia E, França, Ivan L.A, Ribeiro, Ana C, Sallum, Adriana M.E, Bonfa, Eloisa, Silva, Clovis A
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Age Allergy and Immunology Anti-TNF Antibodies, Bacterial - blood Antirheumatic Agents - therapeutic use Arthritis Arthritis, Juvenile - drug therapy Arthritis, Juvenile - immunology Child Child, Preschool Disease Drug dosages Drug therapy Enzyme-Linked Immunosorbent Assay Etanercept Female Gender Hospitalization Hospitals Humans Immune response Immunization Immunogenicity Immunoglobulin G - therapeutic use Juvenile idiopathic arthritis Male Methotrexate - therapeutic use Patients Pneumococcal Infections - prevention & control Pneumococcal vaccine Pneumococcal Vaccines - administration & dosage Pneumococcal Vaccines - adverse effects Pneumococcal Vaccines - immunology Receptors, Tumor Necrosis Factor - therapeutic use Rheumatic diseases Seroconversion Streptococcus infections Streptococcus pneumoniae Treatment Outcome Tumor Necrosis Factor-alpha - therapeutic use Vaccines
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!